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countries, particularly depending on ethnicity and level of participation in the BCS 
programme. The model predicted a significant increase in the number of deaths 
associated with BC in Korea; a disinvestment decision, however, would not have a 
large impact on the number of deaths, due to currently high levels of overdiagno-
sis, and overall costs would be significantly reduced. A disinvestment decision in 
Australia would dramatically reduce the number of overdiagnosed women, although 
mortality due to BC would be higher. ConClusions: This analysis has shown that 
the cost-effectiveness of BCS programmes should be evaluated over the long-term 
in order to take into account the consequence of overdiagnosis. Disinvestment 
decisions are complex and must be made locally, taking into consideration specific 
characteristics of the population under study.
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objeCtives: Trastuzumab, a monoclonal antibody, has been widely used in treat-
ment of HER2-positive breast cancer because of its proved effectiveness and safety. 
However because of the high price, the cost-effectiveness of trastuzumab should 
be evaluated especially in such low-income country as Vietnam. This is also the 
aim of this study. Methods: A Markov model has been constructed with 5 health 
states (disease-free survival, local recurrence, regional recurrence, metastatic, 
death) with 1-year cycle length and lifetime horizon. The transition rates between 
states have been retrieved from relevant epidemiological studies, clinical trials and 
experts’ opinions. A population of 1000 50-year-old women with average weight of 
60 kg has been included in model. Lists of medical services and drugs were derived 
from NCCN guideline 2014. The prices of drugs and medical services have been 
averaged from the price-lists in 2013 of some major hospitals in Vietnam. Both 
QALYs and cost were discounted at 3%. Probabilistic sensitivity analysis was also 
conducted. Results: 1-year trastuzumab adjuvant therapy of HER2-positive early-
stage breast cancer costed VND 936,459,291.67 for life-time horizon and resulted 
in 10.07 QALYs. Standard chemotherapy costed VND 227,092,425 and resulted in 
7.32 QALYs. Therefore 1-year trastuzumab adjuvant therapy costed an addition 
amount of VND 709,4 million and resulted in added QALY of 2,75 years. CER of 
trastuzumab group is 3 times higher than no trastuzumab group (VND 91 million vs 
30 million, respectively). The incremental cost-effectiveness ratio (ICER) resulted in 
VND 265,115,616.93. One-year trastuzumab adjuvant therapy has been considered 
to be cost-effective when comparing with willing-to-pay (WTP) of Vietnam (VND 
253,503,360.00). Sensitivity analysis showed that the most affecting factor on the 
cost-effectiveness of trastuzumab is its price. ConClusions: 1-year trastuzumab 
adjuvant therapy of HER2-positive early-stage breast cancer is cost-effectiveness in 
Vietnam. Trastuzumab’s price is the most affecting factor on its cost-effectiveness.
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objeCtives: With the developing of new technology for genetic test, the accuracy 
of predicting the risk that a patient may diagnose with breast cancer in future was 
increased dramatically. But considering that after diagnosis with breast cancer, 
those women has doubled prevalence of diagnosed with depression compared with 
general female population, and the anxiety patient suffered after realized taking 
specific mutations, which high likely led to breast cancer, before really diagnosed 
with breast cancer. There is no doubt that depression is a serious issue for patient 
with high risk of developed breast cancer. Moreover, the drug interaction between 
antidepressants and tamoxifen reduces the effect of tamoxifen, and complicates 
the decision-making. This cost-effectiveness study tries to use Markov model to 
investigate the best strategy that gives to high-risk breast cancer patients after 
genetic test and diagnosed with breast cancer. Methods: A cost-effectiveness 
study using Markov model will be conducted from a third payer perspective. Both 
time and different antidepressants from desipramine, fluoxetine, paroxetine, mian-
serin, melatonin to escitalopram will be included in this study as different expo-
sure. Life-long quality of life will be calculated as outcome. In order to investigate 
the extent of accuracy, one way sensitivity analyses and probabilistic sensitivity 
analysis will be conducted. Results: Mianserin, melatonin does not interfere with 
tamoxifen treatment, under that situation, these medication have the best outcome. 
The time period from diagnosed with breast cancer till 1 year is the best timing to 
give antidepressants, which may significantly change the outcome. ConClusions: 
Even though, sometimes patients with breast cancer may not realize they already 
threaten by depression, the antidepressant still significantly important to breast 
cancer population to prevent the progression of depression with better outcome.
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objeCtives: To evaluate the cost-effectiveness of nodal staging surgery before 
chemoradiotherapy (CRT) for locally advanced cervical cancer (LACC) in the era 
of PET/CT. Methods: A modified Markov model was constructed to evaluate cost 
effectiveness of para-aortic staging surgery before definite CRT when no uptake is 
recorded in para-aortic lymph nodes (PALN) on PET-CT. Survival and rates of compli-
cations were estimated based on the published literatures. Cost data was obtained 
from Korean National Health Insurance database. Strategies were compared using 
an incremental cost-effectiveness ratio (ICER). Sensitivity analyses were performed 
including an estimate for performance of PET/CT, postoperative complication rate, 
estimates were based on results of clinical studies and on information from the list 
of medical and economic charges of Republic of Kazakhstan (2009 y) and the retail 
price of pharmacies in Karaganda. Data sources: PubMed, the Cochrane library, 
Internet search was performed to analyze the results of clinical studies of treat-
ment patients with breast cancer. Results: One-year survival rate was higher by 
21.8% in patients receiving chemotherapy with “Arglabin” compared with patients 
receiving chemotherapy alone. Indicator “cost-effectiveness” for the scheme with 
Arglabin was 281,8 (the cost of one course of treatment is 281,8 $ on one survivor 
patient). Indicator “cost-effectiveness” for the standard scheme CMF was 367,5 (the 
cost of one course of treatment is 367,5$ on one survivor patient). ConClusions: 
The study was identified efficiency and economic benefit of therapy with “Arglabin”. 
Arglabin is effective and safety as additional agent to standard treatment and the 
implementation of this drug to standard therapy of breast cancer will improve the 
outcomes and reduce the costs.
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objeCtives: Number of expensive anti-cancer drugs is increasing. It is impor-
tant to assess cost-effectiveness of such high-cost drugs, however cost data, 
which is applicable to economic evaluation, are not accumulated enough in Japan. 
Therefore we analyzed large claim database to obtain treatment costs for breast 
cancer. Methods: We used JMDC (Japan Medical Data Center) claims database, in 
which claim data of approximately 1.5 million insured people are collected from 
January 2005 to September 2013. We analyzed treatment costs of (a) adjuvant chemo-
therapy, (b) hormone therapy and (c) chemotherapy for metastasis. Breast cancer 
was defined by disease name including claim date (C50 of ICD-10). Since no ICD-10 
code directly indicates metastatic breast cancer, combination of codes such as C780 
(metastasis to lung), C787 (to liver) and C793 (to brain) was used to extract meta-
static patients. We calculated monthly average costs and total costs for treatment 
period. Results: Approximately 400 patients receiving adjuvant chemotherapy 
were identified. Use of taxane (+ JPY 450,000 [USD 4,500, USD1 = JPY100])), trastu-
zumab (+ JPY 2.2 million [USD 22,000]) and hormone therapy (+ JPY 300,000 [USD 
3,000]) significantly influenced on the treatment costs per patient. Most frequently 
administered regimens were DC (D: Docetaxel, C: Cyclophosphamide), FEC+D (F: 
5-FU, E: Epirubicine) EC+D, and FEC. Costs of hormone therapy for metastatic breast 
cancer was averagely about JPY 110,000 [USD 1,100] per month. Tamoxifen was most 
widely used drug, followed by letrozole, anastorozole and exermestan. Average costs 
of chemotherapy was JPY 180,000 [USD 1,800] per month for patients without receiv-
ing molecular targeting therapy. It increased to JPY 360,000 [USD 3,600] per month if 
molecular targeting drugs were used. ConClusions: We can estimate treatment 
costs of breast cancer from the large Japanese claim database. These data are useful 
when cost-effectiveness analysis is performed.
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objeCtives: Organised, nationwide screening for breast cancer with mammogra-
phy in the age group 45-65 years with 2 years screening interval started in Hungary 
in January 2002. The aim of this study is to analyze the health insurance expen-
ditures of breast cancer treatment. Methods: The data derive from the financial 
database of the National Health Insurance Fund Administration (NHIFA) covering 
the 2010 year. The analysis of health insurance costs included outpatient costs of 
mammography screening, hospital costs of breast surgery, the cost of kemo- and 
radiotherapy. Results: The total annual health insurance cost of the National 
Health Insurance Fund Administration is estimated 12.09 billion Hungarian Forint 
(HUF) or 58.09 million dollar (USD). Most of them (61.0 %) releted to the cost of 
chemotherapy (7.38 billion HUF or 35.46 million USD). The next largest cost item 
(20.9 %) is the cost of radiotherapy (2.53 billion HUF or 12.16 million USD). Surgical 
treatment (1.14 billion HUF or 5.47 million USD) of breast cancer and cost of mam-
mography screening (1.04 billion HUF or 5.00 million USD) represents both similar 
volume (9.4 and 8.6 % respectively). ConClusions: The costs related to breast 
cancer screening and treatment showed an increasing trend in the past years. The 
most important cost item is the cost of chemotherapy.
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objeCtives: Disinvestment decisions are made when existing health technologies 
do not fulfil criteria such as efficacy, effectiveness or safety. Breast cancer screening 
(BCS) using mammography is widely implemented; yet many studies show that a 
significant percentage of women are overdiagnosed and overtreated. The objective 
of this study is to analyse the effects of a BCS disinvestment decision in Asia-Pacific 
countries, and to explain any differences between countries. Methods: A math-
ematical model was developed to analyse population outcomes and costs associ-
ated with breast cancer (BC) from 2014 to 2050 in Australia and Korea. Population 
outcomes were measured as number of women diagnosed with BC, number of 
women overdiagnosed and number of deaths associated with BC. The model allowed 
the analysis of these outcomes with and without a BCS programme in place, as a 
proxy to evaluate the effects of disinvestment. Results: Results varied between 
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chemotherapy. Methods: We performed a systematic literature search of the 
EMBASE, MEDLINE, Cochrane Library, Google Scholar, ABI/Inform, and the Web 
of Science using such search terms “filgrastim,” “pegfilgrastim,” “cost analysis,” 
and “economic evaluation.” Studies were limited to primary research in patients 
with solid tumor cancer, specifically, studies comparing filgrastim with pegfil-
grastim and resulting in full manuscripts. Identified studies were evaluated by 
the Drummond checklist6 and characterized by study perspectives, time horizon, 
data sources, and funding. Results: Six studies fulfilled the inclusion criteria. 
Most studies modeled hypothetical cohorts of women aged 30-80 years with breast 
cancer (Stages I-III) from a payer’s perspective. The median Drummond score was 
9 of 10 (range, 8-9). Methodological and reporting variations were common. Key 
assumptions were made about FN-related deaths during chemotherapy, hospi-
talization and outpatient management, chemotherapy costs, and data sources. All 
six studies were funded by the drug manufacturer. Pegfilgrastim was found to be 
cost-saving compared to 11-day filgrastim. However, when compared to 6-day fil-
grastim, the choice of intervention depends on the decision-maker’s willingness-
to-pay. ConClusions: Variations in methodology, reporting, and assumptions 
made comparisons between studies difficult and may explain in part the observed 
results reported in EEs. Studies independent of industry sponsor are needed to 
make conclusive interpretations.
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objeCtives: Cost-effectiveness analysis and cost-utility analysis were adopted to 
evaluate the tertiary breast cancer screening and diagnosis system in Guangdong 
province. Methods: Using data from Guangdong project to evaluate the validity 
and reliability of screening strategies. The intervention group received tertiary 
screening and diagnosis system, while control group received routine screening. 
The actual cost, detection rate and cost-effectiveness ratio were calculated. The 
Markov simulation model was constructed based on the natural history of breast 
cancer with TreeAge Pro 2011. The model was running over thirty years (each 
cycle represents one year). The sensitivity analysis was performed for incidence of 
breast cancer and health state utility. Results: The intervention group involved 
26224 females while the control group involved 24282. The detection rate of breast 
cancer (1/10 million) was 91.54 and 28.86. The percentage of early stage breast 
cancer was 45.83% and 28.57%, respectively. The highest detection rate was found 
in women aged from 45 to 65. In order to detection one case of breast cancer, 
the number need to invite for screening program was 1595. Cost-effectiveness 
analysis was 6152.37yuan per detection rate of breast cancer (1/10 million). During 
the following 30 years, comparing to the control group, the tertiary breast cancer 
screening and diagnosis system for 100 thousand women will reduce 61 cases of 
breast cancer, and save 557.00 LYs, 649.05 QALYs. With the discount rate of 3%, 
Cost-utility analysis was 8142.33yuan per life year saved, 6987.57yuan per QALY 
saved and 74348.84yuan per breast cancer prevented. One-way sensitivity analysis 
showed that parameters had no significant effect on the model. ConClusions: 
Compared to control group, the screening strategy of intervention group improved 
both the detection rate of breast cancer and the percentage of early stage breast 
cancer. The tertiary breast cancer screening and diagnosis system is a preferable 
option for breast cancer screening.
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objeCtives: Our previous research indicated that post-therapy PET scanning may 
obviate the need for hospital-based follow-up in patients with locally advanced 
cervical cancer who achieved a complete metabolic response (CMR). In these 
patients, asymptomatic recurrences were rarely discovered through examina-
tion in the clinic. The aim of this research is to evaluate the cost-effectiveness of 
applying different follow-up strategies in Australia. Methods: A decision analyti-
cal model was constructed to evaluate cost per quality-adjusted life-year (QALY) 
and life-years gained (LYG) by comparing two follow-up strategies: 1) Routine 
hospital-based follow-up and 2) Alternative follow-up involving post-therapy PET 
and nurse-led telephone interview. A model was built using data from a prospec-
tive institutional registry study of 105 consecutive women underwent definitive 
chemoradiation therapy. Based on published institutional data, it was estimated 
that patients who had a complete metabolic response identified by PET, would 
have 5-year overall-survival of 93% and 1.5% recurrence rate, while those with-
out CMR would have a 5-year overall-survival of only 36%.The impact of uncer-
tainty was evaluated using probabilistic sensitivity analysis. Results: Costs for 
Alternative follow-up was estimated to be $25,657 compared with $19,982 for 
Routine follow-up. Alternative follow-up is not cost-saving; this is because the cost 
of PET screening and additional treatment performed on those without CMR is 
more than offset by the cost of intensive hospital-based visits avoided. Preliminary 
modeling suggest that the Alternative follow-up is likely to be cost-effective com-
pared with Routine follow-up with an ICER of $4,094/QALYs gained, given the sur-
vival benefit associated with better targeted salvage therapy and that this result is 
robust to a range of survival gain estimates and other parameters. ConClusions: 
Performing PET scan to evaluate patient’s risk of recurrence is an appealing pros-
pect. This study demonstrated that the alternative follow-up with post-therapy 
PET is likely to be cost-effective when compared to the current practice.
and varying survival rates according to radiation field. Results: We compared 
two strategies: Strategy 1) pelvic CRT for all patients or Strategy 2) nodal staging 
surgery, then extended-field CRT when PALN metastasis is found; otherwise, pelvic 
CRT. ICER for strategy 2 compared to strategy 1 was $19,505 per quality-adjusted life 
year (QALY). Nodal staging surgery was cost-effective at the $50,000 willingness-to-
pay threshold as long as generous survival reduction (> 17%) is found in patients 
who underwent only pelvic CRT despite occult PALN metastasis. The model was 
insensitive to change in performance of PET/CT and postoperative complication 
rates. ConClusions: Nodal staging surgery before definite CRT is potentially 
cost-effective in Korea when PET/CT shows no evidence of para-aortic lymph node 
metastasis. Prospective trials are warranted to transfer these results into guidelines.
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objeCtives: To assess the cost-effectiveness of Afatinib vs. comparators in the 
first-line treatment for patients with non-small cell lung cancer (NSCLC) harbour-
ing epidermal growth factor receptor (EGFR) mutations. Methods: A cost-effec-
tiveness model was applied to assess the costs and effects of afatinib. Data related 
to medical resource use, efficacy of the drugs and health related quality-of-life 
status came from the clinical studies and supported by the results of a Network 
Meta-Analysis (NMA). Direct cost data was obtained from the Bureau of National 
Health Insurance (BNHI) and NHI claims data released by the Collaboration Center of 
Health Information Application. Outcomes included life-years, quality-adjusted life 
years (QALYs), medical costs and incremental cost-effectiveness ratios (ICERs). The 
single-payer (BNHI) perspective is assumed and costs are expressed in New Taiwan 
dollars (NT$). The discount rate of costs and effects is 5%. Results: Treatment 
with afatinib in the 1st line setting extends time in progression-free survival (PFS). 
Compared to gefitinib, patients treated with afatinib in the 1st line setting have 
an increase of 0.05 quality-adjusted life-years (QALYs) and the additional cost is 
NT$21,350.59, yielding an ICER of NT$457,768.67 per QALY gained. Compared to 
erlotinib, patients treated with afatinib have an increase of 0.02 QALYs with less cost 
of NT$-56,216. ConClusions: The results provide decision makers with informa-
tion about the cost-effectiveness of taking afatinib as first-line therapy for advanced 
stage NSCLC by direct comparison of two EGFR-TKIs and cisplatin/pemetrexed. From 
the perspective of the single payer, the afatinib could be a cost-effectiveness strategy 
compared with erlotinib and gefitinib for the 1st line treatment of advanced NSCLC.
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objeCtives: In this study a comprehensive assessment of the cost-effectiveness 
of lenalidomide-plus-dexamethasone compared to dexamethasone, as second-
line or greater than second-line therapy in relapsed/refractory multiple myeloma 
(rrMM) patients was performed, from the perspective of the South Korean National 
Health System. Methods: A Markov-type model was designed to assess the 
long-term costs and effectiveness of lenalidomide-plus-dexamethasone and 
dexamethasone, using patient-level data from the MM-009/MM-010 randomized 
controlled trials. Due to potential crossover-induced bias by subsequent therapies, 
overall survival (OS) was estimated using a quantitative relationship between 
progression-free-survival and OS (censored normal weighted Tobit regression 
model, based on 153 MM studies containing 230 treatment arms). Only direct costs 
were considered (drugs, adverse events and disease monitoring). Effectiveness 
was measured in life years (LY) and quality-adjusted life years (QALY). Costs were 
converted to United-States dollars (1USD= 1,071.33WON). Annual discount rates 
were set at 5% for costs and effectiveness. Probabilistic sensitivity analysis (PSA) 
was conducted with Monte Carlo simulations. Results: For the patient popula-
tion with one previous therapy lenalidomide-plus-dexamethasone is estimated 
to add substantial benefits to dexamethasone, with expected gains of 1.83QALY 
and 2.50LY, offset by a mean incremental cost of $55,387. Corresponding incre-
mental cost-effectiveness ratios are estimated at $30,195/QALY and $22,148/LY. 
PSA revealed a > 95% probability of lenalidomide-plus-dexamethasone being cost-
effective in comparison to dexamethasone at a $40,000 threshold. These results 
are robust against sensitivity analyses in turns of patient sub-populations and 
different crossover correction techniques (simulated treatment comparison; rank 
preserving structural failure time models). ConClusions: Lenalidomide-plus-
dexamethasone can be regarded a valuable treatment option for second or greater 
line therapy in rrMM patients.
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objeCtives: Evidence suggests that primary prophylaxis with filgrastim 
(Neupogen®, administered daily for 10-11 days per chemotherapy cycle) or peg-
filgrastim (Neulasta®, administered once per chemotherapy cycle) is equally 
effective.1-4 Patients often receive shorter (< 7 days) courses of filgrastim in clini-
cal practice.5 Using filgrastim for fewer days may reduce costs, but it has been 
associated with an increased hospitalization risk.5 Economic evaluations (EEs) may 
be used to guide decisions in resource allocation. The objective of this review is 
to identify and characterize the EEs of primary prophylaxis with filgrastim ver-
sus pegfilgrastim in patients with solid tumor cancer receiving myelosuppressive 
